Early transplant-related mortality after cord blood transplantation from unrelated donors (UD-CBT) is close to 50%, mainly due to infectious complications. We have studied the incidence and characteristics of early infections (before day 100) in a series of 27 adult patients (median age 30 years, range 16-46) undergoing UD-CBT at a single institution. All 27 patients experienced at least one infectious episode and 18 (66%) suffered a severe infection. Bacteremia occurred in 55% of patients (13 with Gram-positive and 11 with Gramnegative microorganisms). Eleven of 19 CMV-seropositive patients (58%) developed CMV antigenemia and one patient had CMV disease. Fungal infections were documented in three patients (11%), comprising invasive fungal infections in two cases and a localized esophagitis in one. Ten patients (37%) died before day 100 after transplantation. Infection was considered the primary cause of death in four patients (sepsis by Acinetobacter spp. bacteremia in three cases) and contributed to death in another four. The most striking findings in this series were the high incidence of, and mortality due to multiresistant Acinetobacter spp. and the low incidence of and lack of mortality due to CMV disease. This report confirms that infection is a major complication in adults undergoing UD-CBT. Bone Marrow Transplantation (2002) 30, 937-943. doi:10.1038/sj.bmt.1703764 Keywords: cord blood transplantation; unrelated donor; hematopoietic stem cell transplantation; infection Cord blood transplantation from unrelated donors (UD-CBT) has emerged as an appealing alternative for patients with hematological malignancies or bone marrow (BM) failure who lack a matched unrelated BM donor.
plant-related mortality (TRM) after UD-CBT is close to 50% at day 100. 3, 4 Infections, whether related to delayed engraftment, graft-versus-host disease (GVHD), or impaired immune recovery, are considered to be the major cause of treatment failure. 2 Despite these facts, few reported data regarding the pattern of infection after UD-CBT are available.
The aim of this study was to determine the incidence and characteristics of early infections (before day 100) in a series of 27 consecutive adult patients from a single institution who underwent UD-CBT with standardized conditioning and GVHD prophylaxis, and followed the same supportive care and anti-infectious regimen.
Patients and methods

Patients
Twenty-seven consecutive adult patients with hematological malignancies who underwent UD-CBT at our institution between May 1997 and August 2001 formed the basis of the present study. Eligibility criteria for UD-CBT, the criteria for selection of a CB unit, and the techniques used for HLA typing of patients and CB grafts have been described elsewhere. 4, 5 Preparative regimen and GVHD prophylaxis Twenty-six patients were conditioned with thiotepa, busulfan, cyclophosphamide and antithymocyte globulin (ATG), as described in detail elsewhere. 4, 5 The remaining patient was treated with a conditioning regimen of reduced intensity, consisting of fludarabine, thiotepa, and ATG. 4 Subcutaneous filgrastim (Amgen, Thousand Oaks, CA, USA) was administered to all patients from day 7 after transplant in an attempt to shorten the time to engraftment. 4 Cyclosporine and prednisone were used for GVHD prophylaxis. 4 Patients developing acute GVHD received high-dose methylprednisolone. ATG was administered as second-line therapy in refractory cases.
Supportive care and anti-infectious prophylaxis
Patients were nursed in high-efficiency particulate air (HEPA)-filtered rooms. Intravenous access was achieved with a double-lumen tunneled central venous catheter. Transfused blood products were irradiated and leukocytedepleted. Anti-infection prophylaxis was begun immediately after admission to the bone marrow transplantation unit. All patients received oral ciprofloxacin (500 mg twice daily) as antibacterial prophylaxis. Prophylaxis against Pneumocystis carinii-induced pneumonia consisted of cotrimoxazole (320/1600 mg trimethoprim/sulfamethoxazole daily) from day Ϫ10 until day Ϫ2. It was restarted after engraftment and maintained until day +180 (administered 2 days a week). Oral nystatin, fluconazole (100 mg/day orally) and aerosolized amphotericin B (5 mg three times daily) were administered as prophylaxis against fungal infections. Cytomegalovirus (CMV)-seropositive patients received acyclovir (400 mg/m 2 per 12 i.v.) from day Ϫ5 until engraftment, followed by ganciclovir (5 mg/kg per day i.v., three times per week) until day +100. In the 13 CMVseropositive patients transplanted after January 2000, ganciclovir was administered at the same dose, for 5 days per week. CMV-negative recipients were only given acyclovir for viral infection prophylaxis. Non-specific intravenous immunoglobulin was administered at a dose of 500 mg/kg weekly to day +100 and then monthly during the first year after transplant. Patients developing acute GVHD received oral itraconazole (100 mg/day, capsules) or fluconazole (200 mg/day, capsules) for the period they received steroid therapy.
Definitions and classification of febrile episodes
Fever was defined either by an axillary temperature у38°C on two separate occasions at least 1 h apart, or Ͼ38.5°C on a single occasion. Neutropenia was defined as an absolute neutrophil count (ANC) Ͻ1 ϫ 10 9 /l. In accordance with the guidelines issued by the Immunocompromised Host Society Consensus Conference 6 and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), 7 primary febrile episodes were classified as follows: (1) microbiologically documented infection (MDI) with or without bacteremia; (2) clinically documented infection (CDI); (3) fever of unknown origin (FUO); and (4) noninfectious fever. 'CMV infection' or CMV reactivation was defined as a CMV-pp65 antigenemia of any positive cell. CMV pneumonitis was confirmed by detection of virus in bronchoalveolar lavage (BAL) using any method of detection (PCR, pp65 antigen detection, culture, shell vial), and by the presence of lung infiltrates on chest X-rays, plus dyspnea. CMV gastrointestinal tract infection was confirmed by biopsy showing CMV cell inclusions, immunofluorescence, or in situ hybridization for CMV; or by positive CMV viral cultures plus symptoms of CMV infection in the gastrointestinal tract. The 'CMV syndrome' was defined by fever, pancytopenia, and CMV antigenemia. 8, 9 Invasive fungal infections (IFI) were defined as possible, probable, or proven, according to published consensus criteria. 10 Severe infection was defined as bacteremia by any organism in a febrile patient (except for coagulase-negative staphylococci (CNS), Micrococcus, or saprophytic Corynebacterium species), IFI, CMV reactivation or CMV disease, septic shock, or pneumonia.
Clinical and laboratory evaluation of infections
Clinical evaluation of febrile patients included a complete medical history and physical examination. Before the start of antibiotic therapy, samples for at least two sets of blood cultures (at 20-min intervals) were collected through the two-lumen catheter and peripheral vein. Samples were taken daily through the catheter if fever persisted. In those patients receiving high-dose methylprednisolone, surveillance blood cultures were grown weekly. We used an automated BACTEC 9240 (Becton Dickinson, Sparks, USA) or BacT/Alert (Organon Teknika, Durham, USA) system to process blood culture samples. Single blood culture isolates were sufficient to classify an episode as bacteremic, except for CNS and Corynebacterium species other than C. jeikeium, which required at least two positive blood culture specimens. Oral and nasal swabs were taken prior to antibiotic therapy and then at least once weekly. Patients were monitored for CMV antigenemia by leukocyte expression of the CMV-pp65 antigen twice weekly until day +120, and once weekly from day +120 to +180. Serological tests for Aspergillus gallactomannan antigen (Platelia Aspergillus enzyme-linked immunosorbent assay; Sanofi Diagnostic Pasteur, Marnes la Coquette, France) were performed twice weekly in 22 patients after 1999. All stool samples were examined microscopically for Cryptosporidium and other intestinal parasites, including Giardia lamblia. Stools were cultured for Salmonella, Shigella, Campylobacter and Escherichia coli 0157. Liquid stool samples were also tested for Clostridium difficile toxin and for viruses. When possible and when clinically indicated, we collected cultures from other clinically suspicious sites of infection, including samples of bronchoalveolar lavage or fibrobronchoscopic brushing.
Antibiotic treatment
Febrile neutropenic patients were initially treated with empirical intravenous antipseudomonal penicillin (piperacillin/tazobactam, 4/0.5 g every 6 h) in combination with amikacin (single daily dose of 20 mg/kg, maximum 1.5 g). All patients received antibiotic therapy for a minimum of 7 days. Glycopeptide and liposomal amphotericin B (3 mg/kg per day) was sequentially added as part of a multi-step strategy if patients remained febrile for 3 and 5 days after the start of initial therapy. If at any time during the study the patient's clinical status deteriorated (eg septic shock, progression of an initial infection, or development of new sites of infection), piperacillin/tazobactam was discontinued and a fourth-generation cephalosporin or a carbapenem was administered in its place. In patients with a microbiologically documented infection, therapy was modified, if necessary, according to susceptibility testing.
Patients who developed CMV antigenemia received preemptive ganciclovir (5 mg/kg every 12 h) for 14 days, or until 7 days after the clearance of CMV antigen from the blood, whichever occurred later. This was followed by a dose of 5 mg/kg of the same drug per day for 5 days per week, over 2 weeks. Those patients who developed a second episode of CMV antigenemia before day +120 received ganciclovir (as above), or foscarnet for 14 days at 60 mg/kg every 12 h. Those who had more than one episode of CMV antigenemia received prophylaxis with oral ganciclovir (3 g/day) or acyclovir (800 mg five times per day) until day +180. Treatment for CMV disease consisted of ganciclovir 5 mg/kg every 12 h for 21 days, plus nonspecific intravenous immunoglobulin (500 mg/kg per 48 h) for 3 weeks.
Other definitions and statistical analysis
Patients surviving more than 30 days after transplantation were considered evaluable for engraftment. Myeloid engraftment was defined as an ANC у0.5 ϫ 10 9 /l on 3 consecutive days. Secondary graft failure was defined as the loss of an engrafted transplant. Acute GVHD was defined and graded according to standard criteria. 11, 12 The infection data were collected until patient death or until day +100. All statistical analyses were carried out with software from the BMDP library.
Results
Patient characteristics
Twenty-seven adult patients (15 men and 12 women; median age 30 years, range 16-46 years) underwent UD-CBT at our institution between May 1997 and August 2001. The main characteristics of the patients are summarized in Table 1 . Nineteen patients were CMV-positive. None of the cord blood units was positive for IgM antibody to CMV. All 24 patients surviving more than 28 days had myeloid engraftment before day +52. The median time to reach an ANC Ͼ0.5 ϫ 10 9 /l, and > 1 ϫ 10 9 /l, was 22 days (range, 13-52 days), and 26 days (range, 14-64 days), respectively.
Type of infection
Seventy-one infectious episodes were registered, with a median of three episodes per patient (range, 1-4). Five patients had one infectious episode and the remaining 22 had two or more. The median time of onset for the first infection was day +3 (range, day Ϫ5 to day +30). Thirtysix of 71 infectious episodes (51%) were documented during the period of neutropenia. Severe infection was observed in 18 patients (66%) over 34 episodes.
As shown in Table 2 , 22 patients (81%) presented with microbiologically documented infections. Nineteen infectious episodes, occurring in 14 patients, were considered to be clinically documented infections. The sites of infection were oral mucositis (nine episodes), pneumonia (seven episodes), and catheter tunnel infection (three episodes). Nine episodes of FUO occurred in nine patients.
Bacterial infections
Twenty-four bacterial infections were documented in 17 patients (Table 3) . Ten bacterial infections occurred while Bone Marrow Transplantation CML = chronic myeloid leukemia; CP1 = first chronic phase; CP2 = second chronic phase; AP = accelerated phase; BC = blast crisis; ALL = acute lymphoblastic leukemia; CR1 = first remission; CR3 = third remission; AML = acute myeloblastic leukemia; MDS = myelodysplastic syndrome; TT = thiotepa; BU = busulfan; CY = cyclophosphamide; ATG = antithymocyte globulin; FLU = fludarabine; CMV = cytomegalovirus; a HLA-A and -B by low-resolution and HLA-DRB1 by high-resolution techniques. patients were neutropenic, whereas 14 appeared after myeloid recovery. Thirteen episodes were due to Grampositive organisms and 11 to Gram-negative rods. Fifteen of the 27 patients (55%) had one or more episodes of bacteremia (21 episodes). In 11 cases, bacterial infection was considered to be severe. Seven of these occurred during the period of neutropenia. Sepsis associated with multiresistant Acinetobacter spp bacteremia was the cause of death in three patients. Two of them died before myeloid engraftment, on days +10 and +25, and the remaining patient died on day +40. This patient had previously suffered an episode of sepsis and meningitis due to Streptococcus pneumoniae. In all three patients with Acinetobacter spp bacteremia, this microorganism was isolated during or after a stay in the intensive care unit. Only one of the three patients had been previously treated with a cephalosporin.
Viral infections
The rate of CMV reactivation in the overall series was 41%, while only one patient had a CMV-associated disease. Eleven of the 19 CMV-seropositive patients (58%) developed CMV reactivation at a median of 35 days after UD-CBT (range, 23-100 days). Thirteen cases of antigenemia were documented in 11 patients; two patients had two antigenemia episodes and one of them also had associated CMV disease (enteritis). None of the eight CMV-seronegative patients developed CMV infection or CMV disease. The incidence of CMV antigenemia did not differ between patients assigned to receive three or five weekly doses of prophylactic ganciclovir (four of six patients vs seven of 13 patients, respectively). One patient presented with a necrotic perioral mucocutaneous infection due to herpes simplex virus. This infection was clinically resistant to acyclovir, but responded to foscarnet.
Other infections
Three episodes of fungal infection (11%) occurred in three patients, one early onset candidemia (day +15) due to Candida parapsilosis that had a favorable outcome with antifungal treatment and removal of the central venous catheter; one mixed fungal bronchopneumonia (Candida spp and Aspergillus spp) diagnosed at autopsy in a patient who died on day +44 due to acute refractory GVHD; and one localized Candida albicans esophagitis on day +78. Parasitic infections were documented in two patients with refractory acute GVHD. One of them presented with a recurrent infection due to Giardia lamblia starting on day +25, and the other patient developed cerebral toxoplasmosis on day +40. Although the outcomes of these infections were originally favorable in both patients, cerebral toxoplasmosis reappeared 3 months later in the context of extensive chronic GVHD.
Outcome
Overall, TRM at day +100 was 37% (10 deaths among 27 patients). As shown in Table 4 , infection was considered the primary cause of death in four patients (40%, sepsis by multiresistant Acinetobacter spp in three patients and pneumonia without microbiological documentation in one), and contributed to death in another four (invasive aspergillosis in one patient, pneumonia in two patients, and cerebral abscesses in one). The remaining two patients died as a consequence of pulmonary hemorrhage and CNS regimenrelated toxicity.
None of the analyzed variables (sex, age and weight of the recipient, stage of the disease at transplant, ABO match, degree of HLA mismatch, number of nucleated cells infused, GVHD and ANC) showed a statistically significant association with severe infection, CMV infection, or infection-related mortality rates. We also compared postengraftment mortality according to whether or not patients developed severe infection during the pre-engraftment period. Those developing severe infection during the preengraftment period (nine patients) and those who did not developed such severe infection (18 patients), showed a mortality of 33% and 22% during the post engraftment period (three and four cases, respectively). This difference was not statistically significant.
Discussion
Infections are a major cause of morbidity and mortality in patients undergoing allogeneic BMT. 13, 14 They are more frequent and severe after unrelated donor hematopoietic stem cell transplantation (UD-HSCT), compared with transplants from HLA-identical siblings. [15] [16] [17] [18] [19] Despite the pivotal role of infectious complications in the outcomes of UD-HSCT, there has been no published study to date regarding the pattern of infections after CBT. However, in the previously reported CBT series of pediatric patients, the main causes of death in the first 100 days after transplant were infection and acute GVHD. 3, 4, [20] [21] [22] [23] [24] In children, UD-CBT results in a longer period of neutropenia than does matched 941 Table 4 Causes of death UD-BMT. 24 However, this does not seem to be the only cause of the higher infection rate. 22 Prolonged hospitalization, acute GVHD, immunosuppressive therapy, and impaired immune response may also contribute to the infections seen in these patients. The high incidence of severe bacterial infections observed in the present series, once neutropenia had been resolved, was remarkable.
The most striking feature of the present series is the higher-than-expected incidence of Gram-negative infections. This contrasts with the pattern of infections reported in recent series of HSCT, 18, 19, [25] [26] [27] [28] which consistently showed a decreasing occurrence of Gram-negative infections, mainly due to specific prophylaxis. A possible explanation for our findings is the increasing appearance of fluoroquinolone-resistant Gram-negative bacillus strains. 29 However, only four of the 11 infectious episodes by Gramnegative microorganisms were resistant to ciprofloxacin, and three of these involved multiresistant bacilli. Other peculiarities of the UD-CBT procedure, such as delayed engraftment and prolonged hospital stay, may explain the incidence of Gram-negative infections. The occurrence of and mortality from bacteremia due to Acinetobacter spp (three of 27 patients) is also remarkable. This is an emergent pathogen in the hospital environment, especially in intensive care units, 30 which produces severe infections in immunocompromised hosts and is resistant to the most common antibiotics. 31 Adding colistin to the prophylaxis regimen in high-risk patients and limiting the patient's admission into intensive care units as far as possible may be a reasonable strategy with which to minimize Acinetobacter spp infections in UD-CBT. 32 In the present series, the CMV reactivation rate was similar to, or even lower than that observed after related-donor and UD-BMT. 17, 18, 33 This finding is probably due to ganciclovir prophylaxis, with a three to five times per week regimen, in those patients at risk (CMV-seropositive). 34 Ganciclovir prophylaxis not only reduces the rate of CMVassociated disease, but also the number of CMV reactivations in recipients of BMT from HLA-identical sibBone Marrow Transplantation lings. [34] [35] [36] Our results, with only one case of CMV disease, suggest that ganciclovir prophylaxis may also be useful in patients undergoing mismatched UD-CBT. However, this assertion should be accepted with caution until confirmatory data from larger series become available. In fact, ganciclovir prophylaxis has been found to be inadequate in recipients of matched UD-BMT, 36 as well as in patients receiving T cell-depleted marrow grafts. 33, 37, 38 Data from one institution have suggested that a five times per week schedule of ganciclovir prophylaxis is superior to a three times per week schedule. 33 Due to our small sample size, we were unable to confirm this observation. Ganciclovir prophylaxis has also been associated with a higher incidence of fungal infection. 35 In the present series, the incidence of fungal infection was low, despite the use of prophylactic ganciclovir and prednisone in most patients. The reasons for this finding are unclear.
In summary, in the present series of adult patients undergoing UD-CBT, infection was a major cause of morbidity and mortality within the first 100 days after transplant. The most important findings were the greater than expected incidence of Gram-negative infection, particularly multiresistant Acinetobacter spp sepsis, and the low incidence of CMV disease and the absence of mortality from it. Strategies for patients undergoing UD-CBT should be aimed at the enhancement of prophylaxis, early diagnosis of potentially severe infections, and the improvement of current antibiotic therapies.
